Old-fashioned antithrombotic drugs: will they be sent to a museum?
DOI:
https://doi.org/10.24265/horizmed.2022.v22n2.00Abstract
The development and prescription of drugs that alter the hemostatic balance marked an important breakthrough in the treatment and prevention of thromboembolic events, which has drastically reduced the associated morbidity and mortality. The discovery of heparin and coumarin anticoagulants, as well as the description of their thrombotic activities, opened a new therapeutic scenario.
Downloads
References
McLean J. The thromboplastic action of cephalin. Am J Physiol. 1916.
McLean J. The discovery of heparin. Circulation. 1959; 19(1): 75-8.
Campbell HA, Smith WK, Roberts WL, Link KP. Studies on the hemorrhagic sweet clover disease: II. The bioassay of hemorrhagic concentrates by following the prothrombin level in the plasma of rabbit blood. J Biol Chem. 1941; 138(1): 1-20.
Gibson P. Salicylic acid for coronary thrombosis? Lancet. 1948; 1(6512): 965.
Gibson P. Aspirin in the treatment of vascular diseases. Lancet. 1949; 2(6591): 1172-4.
Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy: controlled prospective trial. N Engl J Med. 1975; 292(20): 1046-50.
Kakkar VV, Corrigan T, Spindler J, Fossard DP, Flute PT, Crelling RQ, et al. Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery: a double-blind, randomised trial. Lancet. 1972; 2(7768): 101-6.
Kakkar VV, Corrigan TP, Fossard DP, Sutherland I, Thirwell J. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet. 1975; 2(7924): 45-51.
Columbus Investigators, Buller HR, Gent M, Gallus AS, Ginsberg J, Prins MH, et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med. 1997; 337(10): 657-62.
4th American College of Chest Physicians Consensus Conference on Antithrombotic Therapy. Tucson, Arizona, April 1995. Proceedings. Chest. 1995; 108(Suppl. 4): 312-34.
Baumann MH, Strange C, Heffner JE, Light R, Kirby TJ, Klein J, et al. Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest. 2001; 119(2): 590-602.
Kakkar VV. Efficacy and safety of clivarin and other LMWHs in general surgery: a meta-analysis. Blood Coagul Fibrinolysis. 1993; 4(Suppl. 1): 23-7.
Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002; 162(16): 1833-40.
Wright IS. Experiences with dicumarol (3,3'-methylene-bis[4-hydroxycoumarin]) in the treatment of coronary thrombosis with myocardial infarction; preliminary report. Am Heart J. 1946; 32(1): 20-31.
Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost. 2011; 9(Suppl. 1): 12-9.
O’Connell C, Escalante CP, Goldhaber SZ, McBane R, Connors JM, Raskob GE. Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats. Oncologist. 2021; 26(1): e8-16.
Ruiz Mori E. Antiagregantes plaquetarios. Rev Peru Cardiol. 2006; XXXII(1): 29-38.
Lugo LM, Herrero JL. Tratamiento antitrombótico doble frente a triple. Rev Esp Cardiol. 2019; 18(Supl. A): 27-33.
Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing G-J, et al. Antithrombotic therapy for VTE disease. Second update of the CHEST guideline and expert panel report. Chest. 2021; 160(6): e545-608.
Greer DM. Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. CNS Drugs. 2010; 24(12): 1027-40.
Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism. Blood. 2019; 133(4): 291-8.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
